Expansion opportunities Eg is expanding distribution capacity in Hungary and Europe with new logistics facilities, signaling growing reach and potential for broader contract manufacturing, white-labeling, and distribution partnerships across Central and Eastern Europe.

Biosimilar momentum With a track record of biosimilar launches since 2013 and ongoing R&D investment, there is potential to pursue partnerships for biosimilar supply, joint development, or co-promotion in markets where cost-effective biologics are in demand.

Contract potential Large-scale manufacturing modernization and capacity expansion, particularly in finished products and oncology-focused packaging capabilities, create opportunities for contract manufacturing, fill-finish services, and private-label collaborations for regional and international buyers.

Top employer signals Multiple awards and a strong employer brand indicate stable operations and a skilled workforce, reducing supply risk and enabling reliable partner collaborations, licensure, and long-term supply agreements in difficult-to-source therapeutic areas.

R&D driven value Significant annual R&D investment and focus on high-quality branded generics present opportunities to co-develop differentiated products, leverage regulatory-ready pipelines, and accelerate time-to-market for new therapeutics across cardiovascular, CNS, and diabetology segments.